ReviewJournal of lipid and atherosclerosis2023
Risk Stratification of Cardiovascular Disease according to Age Groups in New Prevention Guidelines: A Review.
Review in Journal of lipid and atherosclerosis, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 2 syntheses or guidelines pooled it, 47 citations in OpenAlex.
- Risk factors of pressure injury in elderly inpatients: a systematic review and meta-analysis.BMC geriatrics · 2025Pooled it
- Efficacy and safety of colchicine post myocardial infarction: a systematic review, meta-analysis and meta-regression analysis of randomized clinical trials.European journal of clinical pharmacology · 2025Pooled it
- Efficacy and Safety of Bempedoic Acid in Patients Aged ≥75 Years Stratified by Varying Statin Exposure: Results From Phase 3 Studies of Bempedoic Acid.Journal of the American Heart Association · 2026 · on this mapTrial
- Independent external validation and head-to-head comparison of guideline-recommended CVD risk prediction models.American journal of preventive cardiology · 2026Article
- Transcriptomic landscape of human cardiac aging: identification of cardioselective age-associated genes and predictive modeling.Biogerontology · 2026Article
- Predicting the Risk of Cardiovascular Diseases in the Elderly Based on Clinical Data and Heart Rate Variability Using Machine Learning.Journal of clinical medicine · 2026Article
- Echocardiographic Findings in Saudi Adults With Type 2 Diabetes Mellitus in the Jazan Region.Cureus · 2026Article
- Association of vascular aging and insulin resistance with cardiovascular outcomes in China: PURE cohort study.International journal of surgery (London, England) · 2026Article
- The role of choline in neurodevelopment.Pediatric research · 2026Review
- The Role of Health Literacy in Cardiometabolic Disease among People with Serious Mental Illness.Community mental health journal · 2026Article
- Development and evaluation of cardiovascular disease risk prediction models for patients with type 2 diabetes.Scientific reports · 2026Article
- Article
- Silent Thyroid, Loud Lipids: The Hidden Link in Asymptomatic Adults.Juntendo medical journal · 2026Article
- Lipid-lowering therapy in Switzerland: time trends in utilization and cost, 2015-2023.Lipids in health and disease · 2025Article
- Article
- Challenges in the prevention, treatment and management of cardiovascular disease among older adults.The Lancet regional health. Europe · 2025Review
- Article
- Article
- Clonal Hematopoiesis of Intermediate Potential in Atrial Fibrillation: A Critical View of Current Knowledge as a Springboard for Future Research.Diagnostics (Basel, Switzerland) · 2025Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Age is a strong risk factor for cardiovascular disease. Accordingly, most cardiovascular risk prediction models have included age as an independent risk factor. There is much evidence that effective management of cardiovascular risk factors improves clinical outcomes even in older adults. However, there are concerns that intensive treatment for older adults increases the risk of adverse events. For hypertensive patients, intensive blood pressure reduction with combination therapy increases the risk of syncope, acute kidney injury, and falls. Intensive glucose-lowering therapy among older patients with diabetes increases the risk of hypoglycemia or cognitive impairment. These findings suggest that a balanced approach for older adults is required to increase the benefits and decrease the risk of side effects. In contrast to older people, the estimated 10-year cardiovascular risk in young and healthy individuals is low. However, the lifetime cardiovascular risk in these patients is actually high. The 2021 European Society of Cardiology guideline on cardiovascular disease prevention in clinical practice has been published. It proposed a different risk stratification and recommendation for treatment according to age group, based on the concept of avoiding undertreatment in young people and overtreatment in older persons. Although the guideline recommends age-dependent risk stratification, risk categories should not be applied to the mandatory initiation of drug treatment. In all age groups, other factors such as lifetime cardiovascular risk, treatment benefit and harm, comorbidities, frailty, and patient preferences should be considered when managing patients for primary prevention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.